Research Article

Effects of Shenkang Injection Combined with Jinshuibao on Early Diabetic Nephropathy and Effects on Coagulation Fibrinolysis System and Urinary Protein

Jianhua Zhu, Tingting Yang, Jie Luo, Mian Wei, Hanyu Li, Yue Qi, Jiali He, and Min Chen

Department of Nephrology, Chengdu Hospital of Integrated Traditional Chinese and Western Medicine, Chengdu, Sichuan 610000, China

Correspondence should be addressed to Min Chen; ccmmsnk@163.com

Received 5 August 2022; Accepted 22 September 2022; Published 11 October 2022

Academic Editor: Fenglin Liu

Copyright © 2022 Jianhua Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To explore the effect of Shenkang injection (SKI) combined with Jinshuibao for early diabetic nephropathy (DN) and its effect on the coagulation fibrinolysis system and urinary protein. Methods. 136 patients with early DN admitted to our hospital from March 2018 to October 2019 were divided into the observation group \((n = 68)\) and the control group \((n = 68)\) randomly. On the basis of the conventional treatment, the control group was treated with SKI, and the observation group was treated with SKI and Jinshuibao. Two weeks later, the therapeutic effects of the 2 groups were compared. The prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB), tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), and D-dimer (D-D) were observed and compared before and after the treatment. 24 hour urine total protein (24h-UTP), urine albumin excretion rate (UAER), and urine \(\beta_2\) microglobulin (\(\beta_2\)-MG) were measured and compared before and after the treatment. Adverse reactions in the two groups were recorded during the treatment. Results. The effective rate of the observation group after treatment was 92.65% higher than the control group 79.41%. The difference was statistically significant \((P < 0.05)\). The levels of PT, APTT, TT, FIB, PAI-1, and D-D in the two groups after treatment were lower, and t-PA levels after treatment were higher than those before, and all of the above indicators were significantly changed in the observation group than in the control group. The difference was statistically significant \((P < 0.05)\). The 24 h-UTP, UAER, and \(\beta_2\)-MG in the two groups after treatment were lower than those before, and all of the above indicators were significantly changed in the observation group than in the control group. The difference was statistically significant \((P < 0.05)\). There was no statistically significant difference during the treatment for 2 groups in terms of adverse reactions. The difference was statistically significant \((P > 0.05)\). Conclusion. SKI combined with Jinshuibao has a significant effect in the treatment of early DN, which can reduce the risk of hyperfunction of coagulation and fibrinolysis system, further reduce the content of urine protein, and delay the process of DN.

1. Introduction

Diabetes mellitus (DM) is a group of chronic metabolic diseases characterised by high blood sugar. Persistent hyperglycaemia directly causes chronic damage to various tissues and organs in the body, such as the retina, heart, kidneys, and vascular nerves, leading to a series of chronic complications of DM [1, 2]. Nephropathy is one of the serious microvascular complications of DM, an important cause of chronic renal insufficiency and also an important cause of disability and death in DM patients [3]. Patients with early diabetic nephropathy (DN) usually present with trace proteinuria, oedema, and few clinical symptoms. At the same time, microcirculatory disorders can occur due to abnormal blood glucose and lipid metabolism, which can lead to changes in the coagulation and fibrinolytic systems such as hypercoagulability and fibrinolytic abnormalities. It is now believed that effective intervention in the early stages of DN can delay or even reverse further deterioration of renal function.

The pathogenesis of DN involves hemodynamic abnormalities, hemorheological changes, glomerular basement
membrane thickening (biochemical metabolic disorders), genetic susceptibility, and other factors [4–7]. Shenkang injection (SKI) is a new class II Chinese medicine consisting of four Chinese herbs, namely rhubarb, Astragalus membranaceus, Salvia miltiorrhiza, and safflower, which are effective in dredging the bowels and purging turbidity, supplementing qi, and activating blood circulation. In recent decades, SKI has been most commonly used in clinics to treat kidney-related diseases. It can inhibit the proliferation of glomerular mesangial cells (MC), reduce the accumulation of extracellular matrix (ECM), and delay glomerular sclerosis so as to improve the renal function of patients and delay the progression of kidney disease [8]. The curative effect is accurate. At the same time, a large number of studies have also confirmed that SKI can improve cardiorenal syndrome, hepatorenal syndrome, COPD, and other diseases. Jinshuibao is a kind of Cordyceps sinensis extract, which has the effects of being antibacterial, anti-inflammatory, reducing serum cholesterol, triglycerides, and lipid peroxides, increasing blood supply to the myocardium and brain, and nourishing the lungs and kidneys [9]. This study investigated the efficacy of SKI combined with Jinshuibao in the treatment of early DN and its effect on the coagulation fibrinolysis system and urinary protein.

2. Materials and Methods

2.1. Research Object. 136 patients with early DN admitted to our hospital from March 2018 to October 2019 were divided into the observation group (n = 68) and the control group (n = 68) randomly. In the control group, there were 37 males and 31 females, with a mean age of 52.1 ± 3.9 years and a mean duration of illness of 5.9 ± 3.5 years; in the observation group, there were 35 males and 33 females, with a mean age of 51.3 ± 3.6 years and a mean duration of illness of 6.4 ± 2.7 years. All the above basic data were compared, and the differences were not statistically significant (P > 0.05) and comparable.

2.2. Diagnostic Criteria

2.2.1. DM Diagnostic Criteria. Referring to the 2004 Chinese guidelines for the prevention and treatment of diabetes [10], with clinical signs of DM + determination of plasma glucose ≥11.1 mmol/L (200 mg/dL); determination of fasting blood glucose (FBG) ≥7.0 mmol/L (126 mg/dL); 2 hours after OGTT test, plasma glucose ≥11.1 mmol/L (200 mg/dL). If any of the above three items were met, it could be used as a diagnostic basis. In the absence of hyperglycaemic crisis, a single blood glucose level up to the diagnostic criteria for DM must be rechecked at a later date for verification.

2.2.2. DN Staging Criteria. Referring to the internationally accepted Mogensen staging [11], i.e., DN stage III: 2 positive urine tests for microalbumin (MA) [urine albumin to creatinine ratio (ACR) 2.5–30.0 mg/mmol (men) and 3.5–30.0 mg/mmol (women) at any time point]; or 24 hour urine microalbumin (U-MA) quantification of 20–200 mg/L; or urine albumin excretion rate (UAER) 20–200 μg/min (30–300 mg/24 h); urine routine protein negative, 24 hour urine total protein (24 h-UTP) <0.5 g; and excluded other factors causing increased urine protein.

2.3. Inclusion Criteria. (1) Meeting the above diagnostic criteria for DM and the Mogensen staging criteria for DN stage III; (2) those who volunteered to participate in this study; and (3) those who were not taking ACEI or ARB class antihypertensive drugs.

2.4. Exclusion Criteria. (1) Persons with chronic glomerulonephritis, nephrotic syndrome, urinary tract infections, urinary stones, and other urological disorders; (2) persons with primary renal insufficiency or renal artery stenosis; (3) persons with elevated blood potassium or abnormal blood creatinine; (4) persons with diabetic ketosis, ketoacidosis or co-infections, and other systemic diseases; (5) patients with cardiovascular and cerebrovascular diseases and disorders of blood clotting; (6) women during pregnancy and breastfeeding; (7) persons who had recently taken antiplatelet or anticoagulant medication or were allergic to the study medication; and (8) persons who had interrupted treatment before completing the prescribed course of treatment, whose efficacy could not be judged or whose data were incomplete.

2.5. Research Methods. Both groups were given oral hypoglycaemic drugs or subcutaneous insulin for blood glucose control, a diabetic diet, and moderate exercise as a general treatment, depending on the condition of the patients. In the control group, SKI (Xi’an Century Shengkang Pharmaceutical Co., Ltd., State Drug Administration Z20040110) was administered 100 ml + 0.9% sodium chloride injection, 250 ml intravenous drip, 1 time/d. In the observation group, Jinshuibao (Jiangxi Jinmin Jinshuibao Pharmaceutical Co., Ltd., State Drug Administration Z10890003) was added on top of the control group for oral administration, 3 capsules/time, 3 times/d. Both groups were treated continuously for 2 weeks.

2.6. Observation Indicators. Efficacy was determined after 2 weeks of treatment [12]. Apparently cured: significant improvement in symptoms such as oedema, significant improvement in all urine protein-related indicators, and control and cessation of the progression of the disease; improved: symptoms such as oedema had improved, all urine protein-related indicators had improved, and renal disease was progressing slowly; invalid: symptoms such as oedema and proteinuria remain and did not improve or the kidneys deteriorate further. Total effective rate = (number of apparently cured cases + number of improved cases)/total number of cases × 100%.

Then, 10 ml of the fasting venous blood was collected from patients before and 2 weeks after treatment, centrifuged, and the serum was prepared. Prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (FIB) by the coagulation method...
and tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), and D-dimer (D-D) by the ELISA method.

Patients’ urine were collected 24h before treatment and 24h after 2 weeks of treatment, and 10ml was taken after thorough mixing for examination. The 24h-UTP was measured by urine protein precipitation and the biuret method, and urine β2 microglobulin (β2-MG) and MA concentrations were measured by immunoturbidimetric assay and UAER was calculated.

The adverse reactions of patients in both the groups were observed during the treatment period.

2.7. Statistical Methods. The SPSS22.0 software was applied for processing and the count data were expressed as rate (%) using the χ2 test. The measurement data were expressed as mean ± standard deviation (X ± s) and the t-test was used for two-way comparison between groups. The test level was α = 0.05 and P < 0.05 was considered a statistically significant difference.

3. Results

3.1. Comparison of Post-Treatment Outcomes for 2 Groups. As shown in Table 1, after treatment, the effective rate of the observation group 92.65% was higher than the control group 79.41%, the difference was statistically significant (P < 0.05).

3.2. Comparison of Coagulation and Fibrinolytic Parameters for 2 Groups. As shown in Figure 1, before treatment, there was no significant difference in all coagulation and fibrinolytic parameters for 2 groups (P > 0.05); after treatment, the levels of PT, APTT, TT, FIB, PAI-1, and D-D in the two groups were lower and t-PA levels was higher than those before treatment, and the levels of PT, APTT, TT, FIB, PAL-1, and D-D in the observation group were lower, and the levels of t-PA were higher in the observation group than those in the control group. The difference was statistically significant (P < 0.05).

3.3. Comparison of Urine Protein Indicators for 2 Groups. As shown in Figure 2, before treatment, there was no significant difference in the comparison of all urine protein indicators for the 2 groups (P > 0.05); after treatment, 24 h-UTP, UAER, and β2-MG in the two groups were lower than those before treatment, and 24 h-UTP, UAER, and β2-MG in the observation group were lower than those in the control group; the difference was statistically significant (P < 0.05).

3.4. Comparison of Adverse Reactions for 2 Groups. During the treatment period, there were 2 cases of nausea, 1 case of vomiting, and 1 case of dizziness in the control group, for a total of 4 cases, with an incidence of 5.88% (4/68); 2 cases of nausea, 2 cases of dizziness, and 2 cases of abdominal distension in the observation group, for a total of 6 cases, with an incidence of 8.82% (6/68). Comparison of adverse reactions for 2 groups revealed no statistically significant difference (P > 0.05).

4. Discussion

DN is a serious group of microvascular complications of DM. Its pathogenesis is very complex, including microcirculation disorders caused by abnormal glucose and lipid metabolism, activation of the RASS system, accumulation of advanced glycoprotein products, tissue oxidative stress response, and abnormal expression of the coagulation and fibrinolysis systems [13]. Early DN is mostly manifested by a high glomerular filtration rate, increased renal volume, thickened basement membrane, microalbuminuria, edema, etc. [14, 15]. With the further development of the disease, the intensification of oxidative stress reactions and the continuous destruction of microvascular permeability, the glomerular sclerosis speed is accelerated, and then it develops into a large amount of proteinuria, elevated blood creatinine, hypertension, and even uremia [16]. Therefore, early treatment of DM is of great significance.

DN belongs to the category of “oedema,” “deficiency labour,” and “thirst” in traditional Chinese medicine. The early stage of the disease is characterised by clear evidence of “stasis” and “deficiency.” Thus, the treatment of early DN focuses on controlling urine protein, improving kidney microcirculation (i.e., activating blood circulation and removing blood stasis), and nourishing kidney qi. SKI is composed of four herbs: rhubarb, Astragalus membranaceus, Salvia miltiorrhiza, and safflower. Among them, rhubarb can dredge the viscera, remove dirt, eliminate edema, reduce blood creatinine and urea nitrogen, and delay glomerular interstitial fibrosis [17]. Astragalus membranaceus can replenish qi and nourish blood, invigorate righteousness and eliminate pathogenic factors, nourish the heart and dredge the pulse, invigorate the spleen and diuresis, improve glucose metabolism, and expand renal blood vessels and cardiac blood vessels at the same time [18]. Pharmacological research [19] found that the main components of Astragalus membranaceus are astragalus polysaccharides, amino acids, linoleic acid, alkaloids, etc., which can enhance the immune function of the body, reduce the excretion of MA, and inhibit glomerular hypertrophy. At the same time, Astragalus can inhibit the production of transforming growth factor (TGF-B), reduce the level of vascular endothelin and the permeability of renal basement membrane so as to protect renal function and delay the deterioration of the renal function. When the two herbs mentioned above are used together, they both contribute to the improvement of gastrointestinal function. One falls and the other rises in their medicinal properties, dispelling turbidity, resolving stasis, and slowing down the deterioration of the kidney function. Both Salvia miltiorrhiza and safflower can activate blood circulation and improve blood circulation in the glomerulus. Animal experiments [20] showed that SKI could significantly reduce blood creatinine and urea nitrogen levels in 5/6 nephrectomized rats, reduce renal pathological damage, and lower urinary albumin, which may be the mechanism of its action to delay
the progression of renal function deterioration. In addition, SKI has been shown to improve anaemia, increase plasma colloid osmotic pressure, raise plasma albumin, and reduce the amount of albumin in urine [21].

The main component of Jinshuibao is fermented Cordyceps powder. The adenosine, vitamin E, zinc, selenium, and copper contained in it directly participate in the metabolism of SOD, increase SOD, remove free radicals, reduce lipid peroxide, and protect the patient’s kidney from damage. At the same time, it can improve renal blood flow, inhibit platelet aggregation, stabilize the lysosomal membrane, reduce NAG enzyme, maintain renal tubular function, reduce azotemia, protect and maintain renal function, and promote the repair of renal cells; and by regulating hormone secretion, it can enhance cellular immune function and phagocytosis of phagocytes, and play a certain role in the regulation and clearance of blood creatinine, urea nitrogen, and other metabolites. As a result, the internal environment of DN patients is brought from imbalance to balance, thus improving and stabilizing the condition, delaying the process of DN and renal insufficiency, reducing or decreasing the excretion of urinary protein, promoting the repair of renal tubular epithelial cells, inhibiting tubular atrophy and interstitial fibrosis, and achieving renal protection.

Several studies [22, 23] have shown that SKI plays an active role in activating blood circulation and removing blood stasis, improving hemodynamics, and reducing inflammatory reactions in the blood and urinary protein. Jinshuibao can regulate the expression level of signal pathway proteins in patients with DN, which not only has a good curative effect and reduces renal inflammatory reaction but also has the effect of nourishing the kidney

---

**Table 1: Comparison of post-treatment outcomes for 2 groups (n, %).**

| Group           | n   | Apparently cured | Improved       | Invalid   | Total effective |
|-----------------|-----|------------------|----------------|-----------|-----------------|
| Control group   | 68  | 19 (27.94%)      | 35 (51.47%)    | 14 (20.59%)| 54 (79.41%)     |
| Observation group | 68  | 25 (36.76%)      | 38 (55.88%)    | 5 (7.35%)  | 63 (92.65%)     |

χ² value = 4.956

P value = 0.026

---

**Figure 1:** Comparison of coagulation and fibrinolytic parameters for 2 groups (n, x ± s). Note: (a) PT (s). (b) APTT (s). (c) TT (s). (d) FIB (g/L). (e) PAI-1 (μg/L). (f) t-PA (μg/L). (g) D-D (μg/L). * and # represent comparison with the same group before treatment and comparison with the control group after treatment, respectively, P < 0.05.
The results of this study show that after treatment, the observation group was more effective; the indexes related to urinary protein and coagulation and fibrinolysis for 2 groups were better than before, and the observation group changed significantly; there was no significant increase during the treatment in adverse reactions in the observation group. The results further showed that SKI in combination with Jinshuibao for early DN improved the coagulation and fibrinolysis system and did not significantly increase the incidence of adverse effects. The possible reasons for this are that early DN patients mostly have urinary protein, hypercoagulation, and fibrinogenic abnormalities. In this study, the application of SKI has obvious effects of dilating blood vessels, regulating blood lipids, reducing blood viscosity, and inhibiting platelet and red blood cell aggregation, thus increasing renal blood flow, reducing glomerular capillary pressure, improving glomerular blood hypercoagulation, and finally achieving the effect of reducing urinary protein; and the combination of Jinshuibao can further protect the kidney and regulate the oxidative stress response in the kidney so as to effectively improve the course of early DN.

In summary, SKI combined with Jinshuibao has a significant effect in the treatment of early DN, which can reduce the risk of hyperfunction of coagulation and fibrinolysis system, further reduce the content of urine protein, and delay the progression of renal disease in DM patients.

Data Availability
The data used or analysed during the study can be obtained from the corresponding author upon request.

Consent
Informed consent was obtained from all participants.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

References
[1] J. B. Cole and J. C. Florez, “Genetics of diabetes mellitus and diabetes complications,” Nature Reviews Nephrology, vol. 16, no. 7, pp. 377–390, 2020.
[2] A. Avogaro and G. P. Fadini, “Microvascular complications in diabetes: a growing concern for cardiologists,” International Journal of Cardiology, vol. 291, pp. 29–35, 2019.
[3] H. Kim, Y. U. Bae, J. S. Jeon et al., “The circulating exosomal microRNAs related to albuminuria in patients with diabetic nephropathy,” Journal of Translational Medicine, vol. 17, no. 1, p. 236, 2019.
[4] J. Zhang, J. Liu, and X. Qin, “Advances in early biomarkers of diabetic nephropathy,” Revista da Associação Médica Brasileira, vol. 64, no. 1, pp. 85–92, 2018.
[5] K. Azushima, S. B. Gurley, and T. M. Coffman, “Modelling diabetic nephropathy in mice,” Nature Reviews Nephrology, vol. 14, no. 1, pp. 48–56, 2018.
[6] M. Oshima, M. Shimizu, M. Yamanouchi et al., “Trajectories of kidney function in diabetes: a clinicopathological update,” Nature Reviews Nephrology, vol. 17, no. 11, pp. 740–750, 2021.
[7] M. Akhtar, N. M. Taha, A. Nauman, I. B. Mujeeb, and A. D. M. Al-Nabet, “Diabetic kidney disease: past and present,” Advances in Anatomic Pathology, vol. 27, no. 2, pp. 87–97, 2020.
[8] L. P. Luo, P. Suno, L. S. Ren, H. J. Liu, Y. Zhang, and Y. Y. Zhao, “Shenkang injection and its three anthraquinones ameliorates renal fibrosis by simultaneous targeting IKB/NF-κB and keap1/nrf2 signaling pathways,” Frontiers in Pharmacology, vol. 12, Article ID 800522, 2021.
[9] Q. Lu, C. Li, W. Chen, Z. Shi, R. Zhan, and R. He, “Clinical efficacy of Jinshuibao capsules combined with angiotensin receptor blockers in patients with early diabetic nephropathy:
a meta-analysis of randomized controlled trials,” *Evidence Based Complementary and Alternative Medicine*, vol. 2018, Article ID 6806943, 14 pages, 2018.

10 Compilation Group of Chinese Guidelines for the Prevention and Treatment of Diabetes, *Chinese Guidelines for the Prevention and Treatment of Diabetes*, Beijing Medical University Press, Beijing, China, 2004.

11 C. E. Mogensen, C. K. Christensen, and E. Vittinghus, “The stages in diabetic renal disease with emphasis on the stage of incipient diabetic nephropathy,” *Diabetes*, vol. 32, pp. 64–78, 1983.

12 Nephrosis Branch of Chinese Academy of Traditional Chinese Medicine, “Criteria for the diagnosis, classification and assessment of the efficacy of diabetic nephropathy (pilot scheme),” *Shanghai Journal of Traditional Chinese Medicine*, vol. 41, no. 7, pp. 7–8, 2007.

13 N. Samsu, “Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment,” *BioMed Research International*, vol. 2021, Article ID 1497449, 17 pages, 2021.

14 E. A. T. Koch, R. Nakhoul, F. Nakhoul, and N. Nakhoul, “Autophagy in diabetic nephropathy: a review,” *International Urology and Nephrology*, vol. 52, no. 9, pp. 1705–1712, 2020.

15 S. Tan, Z. Chi, Y. Shan, Z. Wen, and W. Li, “Interaction studies of polybrominated diphenyl ethers (PBDEs) with human serum albumin (HSA): molecular docking investigations,” *Environmental Toxicology and Pharmacology*, vol. 54, pp. 34–39, 2017.

16 S. M. Doshi and A. N. Friedman, “Diagnosis and management of type 2 diabetic kidney disease,” *Clinical Journal of the American Society of Nephrology*, vol. 12, no. 8, pp. 1366–1373, 2017.

17 N. Deng, Y. Yi, A. H. Liang et al., “Mechanism of nephrotoxicity of rhubarb in rats,” *Zhongguo Zhongyao Zazhi*, vol. 43, no. 13, pp. 2777–2783, 2018.

18 H. H. Sun, X. L. Chai, H. L. Li et al., “Fufang xueshuantong alleviates diabetic retinopathy by activating the PPAR signaling pathway and complement and coagulation cascades,” *Journal of Ethnopharmacology*, vol. 265, Article ID 113324, 2021.

19 D. Hui, T. Rui-Zhi, L. Jian-Chun et al., “*Astragalus propinquus* Schischkin and *Panax notoginseng* (A & P) compound relieved cisplatin-induced acute kidney injury through inhibiting the mincle maintained macrophage inflammation,” *Journal of Ethnopharmacology*, vol. 252, Article ID 112637, 2020.

20 B. Fu, J. Yang, J. Chen et al., “Preventive effect of Shenkang injection against high glucose-induced senescence of renal tubular cells,” *Frontiers of Medicine*, vol. 13, no. 2, pp. 267–276, 2019.

21 J. J. Zou, X. T. Zhou, Y. K. Chen et al., “A review on the efficacy and mechanism of action of Shenkang injection against chronic kidney disease,” *Biomedicine & Pharmacotherapy*, vol. 132, Article ID 110833, 2020.

22 Z. J. Xu, X. Chao, C. Jiang, T. Wang, and P. Duez, “Investigation on the mode of action of the traditional Chinese medical prescription-yiqihuoxue formula, an effective extravasation treatment for cerebral vascular microemboli in ApoE-/- mice,” *World Journal of Traditional Chinese Medicine*, vol. 6, no. 1, pp. 112–120, 2020.

23 Z. Song, T. Qin, Y. Pan, L. Wu, T. Liu, and Q. Hua, “Shenkang injection improves coagulation in patients with chronic kidney disease: a systematic review and meta-analysis,” *Journal of Traditional Chinese Medicine*, vol. 39, no. 4, pp. 451–458, 2019.

24 Y. Li and G. Xu, “Clinical efficacy and safety of Jinshuibao combined with ACEI/ARB in the treatment of diabetic kidney disease: a meta-analysis of randomized controlled trials,” *Journal of Renal Nutrition*, vol. 30, no. 2, pp. 92–100, 2020.

25 C. Q. Zhang, J. Q. Yin, Q. Xin, Y. Q. Wang, and Z. M. Ge, “Jinshuibao capsule combined losartan potassium intervened early renal damage of hypertension patients of yin and yang deficiency: a clinical research,” *Zhongguo Zhong Xi Jie He Za Zhi*, vol. 33, no. 6, pp. 731–735, 2013.